NRDL

Zai Lab announced that VYVGART, NUZYRA and ZEJULA have been renewed on China’s 2025 NRDL, expanding access for generalized myasthenia gravis, community‑acquired pneumonia/ABSSSI, and maintenance therapy in platinum‑sensitive ovarian cancer. The renewals underscore clinical value, lower patient costs, and position Zai Lab for growth in immunology, infectious disease and oncology, with projected multi‑year revenue uplift and an 18‑22% CAGR through 2028.